The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus

OBJECTIVE: Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular events and decrease the body fat mass in patients with type 2 diabetes mellitus (T2DM). We examined whether or not the SGLT2-inhibitor dapagliflozin can improve the endothelial function associated with a reduction in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugiyama, Seigo, Jinnouchi, Hideaki, Kurinami, Noboru, Hieshima, Kunio, Yoshida, Akira, Jinnouchi, Katsunori, Nishimura, Hiroyuki, Suzuki, Tomoko, Miyamoto, Fumio, Kajiwara, Keizo, Jinnouchi, Tomio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120841/
https://www.ncbi.nlm.nih.gov/pubmed/29607968
http://dx.doi.org/10.2169/internalmedicine.0701-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120841/
https://www.ncbi.nlm.nih.gov/pubmed/29607968
http://dx.doi.org/10.2169/internalmedicine.0701-17

Ejemplares similares